fluspirilene has been researched along with Diabetes Mellitus, Type 2 in 1 studies
Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tabatabaei Dakhili, SA | 1 |
| Greenwell, AA | 1 |
| Yang, K | 1 |
| Abou Farraj, R | 1 |
| Saed, CT | 1 |
| Gopal, K | 1 |
| Chan, JSF | 1 |
| Chahade, JJ | 1 |
| Eaton, F | 1 |
| Lee, C | 1 |
| Velázquez-Martínez, CA | 1 |
| Crawford, PA | 1 |
| Glover, JNM | 1 |
| Al Batran, R | 1 |
| Ussher, JR | 1 |
1 other study available for fluspirilene and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase.
Topics: Animals; Antipsychotic Agents; Coenzyme A-Transferases; Diabetes Mellitus, Type 2; Dopamine; Fluspir | 2023 |